Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

详细信息    查看全文

• 作者：Aaron Brant ; B.S.^a ; ^{abrant@jhmi.edu} ; Max Kates ; M.D.^a ; Meera R. Chappidi ; B.A. ; B.S.^a ; Hiten D. Patel ; M.D. ; M.P.H.^a ; Nikolai A. Sopko ; M.D. ; Ph.D.^a ; George J. Netto ; M.D.^a ; Alex S. Baras ; M.D. ; Ph.D.^b ; Noah M. Hahn ; M.D.^b ; ^c ; Phillip M. Pierorazio ; M.D.^a ; Trinity J. Bivalacqua ; M.D. ; Ph.D.^a
• 关键词：Bladder cancer ; Radical cystectomy ; TURBT ; Neoadjuvant chemotherapy
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：35
• 期：1
• 页码：34.e17-34.e25
• 全文大小：612 K
• 卷排序：35

文摘

We estimate that 38% of pathologic response in patients who receive NAC for muscle-invasive bladder cancer can be attributed to TURBT. Patients who progressed from non-muscle invasive cancer were less likely to respond to TURBT. Identifying which patients respond to NAC and which respond to TURBT is needed to improve the effectiveness of both interventions.